论文部分内容阅读
[目的]探讨前列腺癌雄激素剥夺治疗对患者骨密度及骨代谢的影响。[方法]前列腺癌及前列腺增生患者,每组各30例:前列腺癌患者予以雄激素剥夺治疗,前列腺增生患者予以前列腺切除或相应药物治疗。观察两组患者治疗前及治疗1年后骨密度和骨代谢相关指标的变化。[结果]两组患者治疗前骨密度及骨代谢指标无差异(P>0.05);治疗1年后,前列腺癌组患者骨量减少,骨源性碱性磷酸酶及骨钙素N端片段明显降低,而Ⅰ型胶原羧基末端肽明显升高(P<0.05)。[结论 ]前列腺癌患者予以雄激素剥夺治疗会增加骨量丢失,影响骨代谢,导致骨质疏松。
[Objective] To investigate the effect of androgen deprivation therapy on bone mineral density and bone metabolism in patients with prostate cancer. [Method] Prostate cancer and benign prostatic hyperplasia patients, each group of 30 cases: prostate cancer patients were treated with androgen deprivation, benign prostatic hyperplasia patients or corresponding drug treatment. The change of bone mineral density and related indexes of bone metabolism were observed before treatment and 1 year after treatment. [Results] There was no difference in BMD and bone metabolic index between the two groups before treatment (P> 0.05). One year after treatment, the bone mass, bone alkaline phosphatase and osteocalcin N-terminal fragment in prostate cancer patients were significantly Decreased, while the type Ⅰ collagen carboxyl terminal peptide was significantly increased (P <0.05). [Conclusion] The treatment of prostate cancer with androgen deprivation will increase bone loss, affect bone metabolism and lead to osteoporosis.